Skip to main content

Advertisement

SpringerLink
Log in

Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

  • Rapid Communication
  • Published:
Modern Rheumatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor expression. Cytokine. 2010;51:178–83.

    Article  PubMed  CAS  Google Scholar 

  2. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8.

    Article  PubMed  CAS  Google Scholar 

  3. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum. 1991;34:1076–84.

    Article  PubMed  CAS  Google Scholar 

  4. Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum. 1990;33:388–97.

    Article  PubMed  CAS  Google Scholar 

  5. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852–8.

    Article  PubMed  CAS  Google Scholar 

  6. Klimiuk PA, Sierakowski S, Chwiecko J. Serum interleukin 6 (IL-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis. Pol Arch Med Wewn. 2003;109:119–23.

    PubMed  CAS  Google Scholar 

  7. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507–12.

    Article  PubMed  CAS  Google Scholar 

  8. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol. 2007;17:403–8.

    Article  PubMed  CAS  Google Scholar 

  9. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.

    Article  PubMed  CAS  Google Scholar 

  10. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33–43.

    Article  PubMed  CAS  Google Scholar 

  11. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors gratefully acknowledge the contributions of Hiroshi Takayama and Shunichi Makita of Chugai Pharmaceutical Co., Ltd.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Itabashi Chuo Medical Center, 2-12-7 Azusawa, Itabashi-ku, Tokyo, 174-0051, Japan

    Isamu Yokoe, Shinya Nishio, Hiroshi Sato & Hitomi Kobayashi

Authors
  1. Isamu Yokoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Nishio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hitomi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hitomi Kobayashi.

About this article

Cite this article

Yokoe, I., Nishio, S., Sato, H. et al. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol 21, 710–714 (2011). https://doi.org/10.1007/s10165-011-0474-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-011-0474-z

Keywords

Search

Navigation